Shares of Questcor Pharma QCOR are down 6.5 percent Friday afternoon following reports on Thursday of an Aetna AET review which showed H.P. Acthar was "medically necessary" only for infants with seizures.
Roth Capital analyst Yale Jen called the sell off a chance to buy some stock. Jen noted the bulletin on Thursday was nearly "identical" to the prior policy update from September. The analyst believes the bulletin does not add "negativity" to Questcor fundamentals.
Roth Capital maintains a Buy rating and $47 price target on shares of Questcor.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in